TRIJARDY XR 12.5-2.5-1,000 MG

What it is

TRIJARDY XR 12.5-2.5-1,000 MG is how the CMS NADAC file names this product. The FDA NDC Directory lists it as empagliflozin, linagliptin, metformin hydrochloride, under the trade name “Trijardy XR”.

FDA gives its dosage form as tablet, extended release and its route as oral.

The labeler, the company named on the label, is Boehringer Ingelheim Pharmaceuticals, Inc.

FDA lists it under 3 Established Pharmacologic Classes: Biguanide, Dipeptidyl Peptidase 4 Inhibitor and Sodium-Glucose Cotransporter 2 Inhibitor.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $168.83 for 30 tablets (30 × $5.62766 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 tablets · NADAC explanation codes

All 2 NDCs

• 00597-0385-77 · Boehringer Ingelheim Pharmaceuticals, Inc. · $5.62766 per EA · eff. 2026-09-23 filed
• 00597-0385-86 · Boehringer Ingelheim Pharmaceuticals, Inc. · $5.62766 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

3 other products in the NADAC file share the FDA nonproprietary name empagliflozin, linagliptin, metformin hydrochloride with TRIJARDY XR 12.5-2.5-1,000 MG.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $5.62766 per EA filed.

Of the 71 other products in FDA’s Biguanide class priced per EA, 32 have a higher middle NADAC price and 39 a lower one. The one in the middle is SYNJARDY 12.5-1,000 MG TABLET, at $5.60127 per EA filed (eff. 2026-09-23).

Of the 43 other products in FDA’s Dipeptidyl Peptidase 4 Inhibitor class priced per EA, 21 have a higher middle NADAC price and 22 a lower one. The one in the middle is JANUMET 50-500 MG TABLET, at $5.28403 per EA filed (eff. 2026-09-23).

Of the 39 other products in FDA’s Sodium-Glucose Cotransporter 2 Inhibitor class priced per EA, 27 have a higher middle NADAC price and 12 a lower one. The one in the middle is XIGDUO XR 2.5 MG-1,000 MG TAB, at $9.60825 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $424.65 for 30 tablets, at an average of $14.15485 per EA in 2024 (2024-01-01 to 2024-12-31) for “Trijardy XR” and “Empaglifloz/Linaglip/Metformin”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 112,533 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.